ALKS-5461 (大うつ病性障害)：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Classification 14
3.3 Symptoms and Subtypes of Major Depressive Disorder 16
3.4 Prognosis 17
3.5 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Unmet Needs and Opportunities 28
6.1 Overview 28
6.2 More Effective Pharmacotherapies 29
6.2.1 Unmet Needs 29
6.2.2 Gap Analysis 30
6.2.3 Opportunities 31
6.3 More Favorable Side Effect Profiles 31
6.3.1 Unmet Needs 31
6.3.2 Gap Analysis 32
6.3.3 Opportunities 32
6.4 Rapid Onset of Antidepressant Effects 33
6.4.1 Unmet Needs 33
6.4.2 Gap Analysis 33
6.4.3 Opportunities 33
6.5 Personalized Treatment Approach 34
6.5.1 Unmet Needs 34
6.5.2 Gap Analysis 35
6.5.3 Opportunities 35
7 Pipeline Assessment 36
7.1 Overview 36
7.2 Promising Drugs in Clinical Development 36
8 ALKS-5461 39
8.1 Overview 39
8.2 Efficacy 41
8.3 Safety 42
8.4 Dosing and Formulation 42
8.5 Potential Clinical and Commercial Positioning 43
8.6 SWOT Analysis 44
8.7 Forecast 44
9 Appendix 46
9.1 Bibliography 46
9.2 Abbreviations 49
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 Diagnosed MDD Patients 51
9.4.2 Percent of Drug-Treated Patients 51
9.4.3 General Pricing Assumptions 52
9.4.4 Generic Erosion 53
9.4.5 Pricing of Pipeline Agents 53
9.5 Physicians and Specialists Included in this Study 54
9.6 About the Authors 56
9.6.1 Analyst 56
9.6.2 Therapy Area Directors 56
9.6.3 Global Head of Healthcare 57
9.7 About GlobalData 58
9.8 Disclaimer 58